Table 1.
Baseline demographics and disease characteristics (Safety population)
| Parameter | Patients (N = 61) |
|---|---|
| Age (years), mean (SD) | 66.0 (6.1) |
| Male gender, n (%) | 43 (70.5) |
| Race, n (%) | |
| Caucasian | 60 (98.4) |
| Asian | 1 (1.6) |
| BMI (kg/m2), mean (SD) | 26.0 (4.3) |
| Time since first COPD diagnosis (years), mean (range) | 9.51 (1.8 to 21.0) |
| Smoking status at screening, n (%) | |
| Ex-smoker | 27 (44.3) |
| Current smoker | 34 (55.7) |
| Post-bronchodilator FEV1 (L), mean (SD) | 1.30 (0.42) |
| Post-bronchodilator FEV1 (% predicted), mean (SD) | 50.2 (11.8) |
| 50 to 70% predicted, n (%) | 33 (54.1) |
| 30 to 50% predicted, n (%) | 28 (45.9) |
| COPD Assessment Test, mean (SD) | 20.7 (5.8) |
| Baseline Dyspnea Index, mean (SD) | 6.2 (1.9) |
| Sputum characteristics, mean (SD) | |
| Total cell count (× 106/g) | 5.69 (20.26) |
| Neutrophil cell count (× 106/g) | 4.82 (8.04) |
| Macrophage cell count (×106/g) | 0.354 (0.319) |
| Eosinophil cell count (× 106/g) | 0.142 (0.230) |
| Lymphocyte cell count (×106/g) | 0.007 (0.011) |
| Neutrophil % | 82.7 (9.46) |
| Macrophage % | 11.0 (7.81) |
| Eosinophil % | 3.60 (4.27) |
| Lymphocyte % | 0.180 (0.267) |
| Epithelial cells % | 2.50 (3.80) |
Abbreviations: BMI body mass index, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s